Stefan Scherer
Chief Executive Officer & President 3T Biosciences
Dr. Scherer is physician-scientist with more than 20 years of experience in biopharmaceutical research and development. Before joining 3T, he was president and CEO of ElyxBio, Inc., worked as global head of experimental medicine at Glaxo SmithKline, served as chief medical officer at Cellectis, an allogenic CAR-T company, and was head of early development, strategy, and innovation for U.S. Oncology at Novartis. Prior to Novartis, Dr. Scherer served in key roles at F. Hoffman-La Roche and Genentech, leading the global biomarker and translational medicine department.
Seminars
Wednesday 20th May 2026
Guiding TCR Therapies from Discovery to Dosing Using End-to-End Platform Insights
4:00 pm
- Conducting MABEL calculations and safety studies in organoids to guide dosing
- Characterizing clinical performance early to strengthen development decisions
- Leveraging the end-to-end benefits of a target discovery platform to derisk your product
